Purchase this article with an account.
Barbara Kloeckener-Gruissem, Daniel Barthelmes, Stephan Labs, Christian Schindler, Malaika Kurz-Levin, Stephan Michels, Johannes Fleischhauer, Wolfgang Berger, Florian Sutter, Moreno Menghini; Genetic Association with Response to Intravitreal Ranibizumab in Patients with Neovascular AMD. Invest. Ophthalmol. Vis. Sci. 2011;52(7):4694-4702. doi: 10.1167/iovs.10-6080.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Neovascular age-related macular degeneration (AMD) resulting in decreased central vision severely impairs affected individuals. Current standard treatment is an intravitreal anti-VEGF therapy (ranibizumab), but responses to treatment show large variability. Genetic factors that influence AMD and that affect the outcome of ranibizumab treatment were sought within a sample of Swiss patients.
Changes in visual acuity (VA) after initiation of anti-VEGF treatment were observed during 12 months, and percentiles of VA were calculated. Genotypes of polymorphisms in known AMD susceptibility loci (CFH, CFB, HTRA1, AMRS2, and VEGFA) as well as not yet reported AMD-associated genes (KDR, LRP5, and FZD4) were determined, and their frequencies were compared.
Of the 309 eyes included in the study, 243 completed VA assessment. On average, 3.9 ±2.6 ranibizumab injections were administered. Based on the change in visual acuity, two responder groups were established: 63 eyes were assigned to the poor responders (≤25th percentile) and 63 eyes to the good responders (≥75th percentile). Individuals with genotype CC of p.Y402H in CFH had a decreased chance of positive treatment outcome compared with those with the CT and TT genotypes (P = 0.005 and P = 0.006). In this study, the genotype combination of AG at CFH with CT at FZD4 (SNP rs10898563) promised an increased chance of positive treatment outcome (P = 0.004). Furthermore, the association with the known genetic susceptibility loci CFH, HTRA1, and AMRS2 were confirmed, and a risk-conferring polymorphism in one new locus, LRP5, was identified.
Genetic predisposition may account for the variability in response to anti-VEGF treatment.
This PDF is available to Subscribers Only